- Home
- TAK vs REGN Comparison
TAK vs REGN Comparison
Compare TAK & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TAK | REGN |
|---|---|---|
| Founded | 1781 | 1988 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.6B | 68.8B |
| IPO Year | 2007 | 1995 |
Fundamental Metrics
Financial Performance| Metric | TAK | REGN |
|---|---|---|
| Price | $18.28 | $782.81 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 25 |
| Target Price | N/A | ★ $830.16 |
| AVG Volume (30 Days) | ★ 2.1M | 536.3K |
| Earning Date | 05-13-2026 | 04-29-2026 |
| Dividend Yield | ★ 3.24% | 0.55% |
| EPS Growth | N/A | ★ 8.19 |
| EPS | N/A | ★ 18.95 |
| Revenue | N/A | ★ $5,872,227,000.00 |
| Revenue This Year | $0.16 | $12.45 |
| Revenue Next Year | $1.22 | $10.13 |
| P/E Ratio | ★ $41.25 | $42.62 |
| Revenue Growth | N/A | ★ 20.82 |
| 52 Week Low | $12.99 | $541.00 |
| 52 Week High | $18.90 | $859.34 |
Technical Indicators
Market Signals| Indicator | TAK | REGN |
|---|---|---|
| Relative Strength Index (RSI) | 54.56 | 50.10 |
| Support Level | $17.87 | $732.04 |
| Resistance Level | $18.51 | $818.06 |
| Average True Range (ATR) | 0.20 | 18.32 |
| MACD | -0.04 | -7.38 |
| Stochastic Oscillator | 19.32 | 21.65 |
Price Performance
Historical ComparisonAbout TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.